Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | GFER | P55789 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6339013 | 1.00 | ALDH1A1 (0.36) | ALDH1A1LMNAMAPTMAPK1GFER | |
| SCHEMBL6335863 | 0.83 | ALDH1A1 (0.42) | ALDH1A1LMNAMAPTKMT2A | |
| SCHEMBL6335861 | 0.83 | ALDH1A1 (0.42) | ALDH1A1LMNAMAPTKMT2A | |
| SCHEMBL6335774 | 0.76 | MAPT (0.43) | ALDH1A1LMNAMAPTMAPK1GFER | |
| SCHEMBL6335775 | 0.76 | MAPT (0.43) | ALDH1A1LMNAMAPTMAPK1GFER | |
| SCHEMBL6337577 | 0.75 | MAPT (0.41) | ALDH1A1MAPTMEN1KMT2ANPC1 | |
| SCHEMBL6345336 | 0.75 | MAPT (0.41) | ALDH1A1MAPTMEN1KMT2ANPC1 | |
| SCHEMBL6337218 | 0.72 | L3MBTL1 (0.31) | ALDH1A1L3MBTL1MEN1KMT2A | |
| SCHEMBL6337217 | 0.72 | L3MBTL1 (0.31) | ALDH1A1L3MBTL1MEN1KMT2A | |
| SCHEMBL12126893 | 0.68 | MAOB (0.60) | LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050203144-A1 | Bicyclo[3.1.0]hexane containing oxazolidinone antibiotics and derivatives thereof | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2005-09-15 | — | — | US | disclosed |
| EP-1385834-B1 | BICYCLO[3,1,0]HEXANE CONTAINING OXAZOLIDINONE ANTIBIOTIC AND DERIVATIVES THEREOF | MERCK & CO INC (US) | 2005-09-14 | — | — | EP | disclosed |
| US-6897230-B2 | Bicyclo[3/1/0] hexane containing oxazolidinone antibiotics and derivatives thereof | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2005-05-24 | — | — | US | disclosed |
| EP-1385834-A1 | BICYCLO[3,1,0]HEXANE CONTAINING OXAZOLIDINONE ANTIBIOTIC AND DERIVATIVES THEREOF | Merck & Co., Inc. (US) | 2004-02-04 | — | — | EP | disclosed |
| US-20030125367-A1 | Bicyclo[3,1,0]hexane containing oxazolidinone antibioytics and derivatives thereof | KYORIN PHARMACEUTICAL CO., LTD. | 2003-07-03 | — | — | US | disclosed |
| WO-2003027083-A1 | BICYCLO[3,1,0]HEXANE CONTAINING OXAZOLIDINONE ANTIBIOTIC AND DERIVATIVES THEREOF | MERCK & CO., INC. (US) | 2003-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030125367-A1 | Bicyclo[3,1,0]hexane containing oxazolidinone antibioytics and derivatives thereof | NR4A1, NR0B1, NR1D1 | ALDH1A1 708/4885LMNA 3824/4885MAPT 4217/4885 |
| US-20050203144-A1 | Bicyclo[3.1.0]hexane containing oxazolidinone antibiotics and derivatives thereof | NR0B1, NR4A1, VDR | ALDH1A1 741/4885LMNA 3317/4885MAPT 4148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.